Skip to main content
Premium Trial:

Request an Annual Quote

Zygogen Provides Curis with Transgenic Zebrafish Technology

NEW YORK, Feb 21 - Zygogen of Atlanta will provide Curis with its
proprietary transgenic zebrafish technology for use in genomics-based drug
discovery, Zygogen said Wednesday.

Zebrafish are similar to knockout mice in that they can serve as model
organisms for finding genome-based drug targets, but they offer the
advantage of being faster to breed and less expensive.

Zygogen, founded in 1999, uses Z-Tag, a technology through which it can
design transgenic zebrafish with organs that are labeled and cell lineages
that are delineated.

"We are pleased to provide Curis with access to Zygogen's zebrafish
technology," said Nina Sawczuk, Zygogen's  CEO. "We are confident that our
technology will accelerate their drug screening programs."

This agreement follows closely after the Sanger Center's announcement it
would begin sequencing the full genome of the zebrafish. Other companies,
such as Artemis pharmaceuticals of Tubingen, Germany, are also seeking to
commercialize zebrafish technology to identify potential gene-based drug
targets.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.